Medtronic's fiscal 4th-quarter sales surge nearly 60% thanks to its buyout earlier this year of Covidien, prompting the medical device company to tighten its earning forecast.
Delays in Neovasc’s early feasibility trial for its Tiara transcatheter mitral valve implant and declining 1st-quarter profits push its stock price down.
Delays in Neovasc's (NSDQ:NVCN) early feasibility trial for its Tiara transcatheter mitral valve implant and declining 1st-quarter profits combined to push its stock price down this week.
Elekta shares take a nosedive after the company badly misses expectations with its fiscal 2014 results, prompting the Swedish medtech giant to sack CEO Niklas Savander.
Hansen Medical cuts its 1st-quarter losses and tops Wall Street's earnings estimates.
Shares of Thoratec rise after the heart pump maker beats Wall Street's forecast with its 1st-quarter results, but arch-rival HeartWare slides after just meeting The Street's bottom line.
The FDA approves Nevro's Senza implantable pain device ahead of schedule and allows it claim superiority to other spinal cord stimulation devices; 1st-quarter sales and earnings top expectations.
Siemens misses the mark with its fiscal 2nd-quarter results and says it will slash another 4,500 jobs from its global workforce.